We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Fecal Fat Points to Early Presence of Colorectal Cancer

By LabMedica International staff writers
Posted on 11 Nov 2016
Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, and therefore more accessible screening tests are urgently needed to identify early-stage lesions. More...
Colonoscopy, for example, is a known lifesaver but is costly and unappealing to many people who might otherwise undergo testing.

The use of ultrasensitive, high-speed technology has identified a suite of molecules in the feces of mice that signifies the presence of precancerous polyps and this "metabolic fingerprint" matches changes in both mouse and human colon tumor tissues and suggests a potential new diagnostic tool for early detection of colorectal cancer in a clinical setting.

Scientists at the Washington State University (Pullman, WA, USA) and their colleagues hypothesized that highly sensitive, metabolic profile analysis of stool samples will identify metabolites associated with early-stage lesions and could serve as a noninvasive screening test. They first identified metabolic products from normal colon tissue in both humans and mice and then compared this normal profile to that found in cancerous colon tissues from humans and research mice with polyps in their colons that mimic those in humans.

The investigators applied travelling wave ion mobility mass spectrometry (TWIMMS) coupled with ultra-performance liquid chromatography (UPLC) to investigate metabolic aberrations in stool samples in a transgenic model of pre-malignant polyposis aberrantly expressing the gene encoding the high mobility group A (Hmga1) chromatin remodeling protein. Metabolic extract samples were analyzed by use of a Synapt G2-TWIMMS instrument and chromatographic pre-separation was achieved by use of an ACQUITY UPLC instrument and eluent was introduced to the TWIMMS system via electrospray ionization (ESI) (Waters Corporation, Manchester, UK).

The scientists found that the fecal metabolome of Hmga1 mice is distinct from that of control mice and includes metabolites previously identified in human CRC. Significant alterations were observed in fatty acid metabolites and metabolites associated with bile acids (hypoxanthine xanthine, taurine) in Hmga1 mice compared to controls. Surprisingly, a marked increase in the levels of distinctive short, arginine-enriched, tetra-peptide fragments was observed in the transgenic mice.

Herbert H Hill, Jr, PhD, a professor of Chemistry and senior author of the study, said, “The feces was not exactly the same as the tissue samples, but it had a lot of similarities to the tissue. We found the lipids and fatty acids were changing, and there were also changes in the amino acids. The exciting part is being able to see differences in the stool. This could lead to a noninvasive, more comprehensive early-warning detection method for colorectal cancer.” The study was published on October 4, 2016, in the Journal of Proteome Research.

Related Links:
Washington State University
Waters

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.